» Articles » PMID: 12052456

Stage-dependent Changes in Trabecular Bone Turnover and Osteogenic Capacity of Marrow Cells During Development of Type II Collagen-induced Arthritis in Mice

Overview
Journal Bone
Date 2002 Jun 8
PMID 12052456
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis (RA) is a disease characterized by inflammatory polyarthritis leading to destruction of the joints and reduction in bone mass. However, the relationship between bone mass and turnover is not yet clear in RA patients. To clarify the effect of bone turnover and marrow osteogenic capacity on mass and structure during the development of arthritis, we examined DBA1/J mice for 8 weeks after the first immunization with bovine type II collagen at the age of 9 weeks. Localized arthritis developed at 4 weeks and advanced arthritis at 6 weeks postimmunization. Urinary deoxypyridinoline levels in arthritic mice were significantly higher at 4 weeks, and levels were maintained thereafter. Their serum osteocalcin levels were significantly reduced compared with controls at 2 and 6 weeks, but did not differ significantly from those in the control group at 4 and 8 weeks. Three-dimensional (3D) trabecular bone volume of the proximal tibia measured by 3D microcomputed tomography (micro-CT) in the arthritic mice became significantly lower at 4 weeks and decreased further at 6 weeks compared with controls. Parameters of 3D trabecular bone structure, such as structure model index and trabecular bone pattern factor, were increased at 4 and 6 weeks, respectively. Trabecular osteoclast number increased and bone formation rates decreased at 8 weeks. The number of total bone marrow cells (BMCs), adherent stromal cells, and area of mineralized nodule formation in the tibia of arthritic mice were significantly reduced compared with controls at 6 weeks. Numbers of total fibroblastic colony-forming units (CFU-f) and alkaline phosphatase (ALP)-positive CFU-f colonies also decreased. However, the values of these osteogenic parameters corrected for the total BMCs and/or adherent stromal cells did not differ significantly between the arthritic and control groups. These data indicate that an increase in bone resorption led to the reduction in trabecular bone mass and deterioration of 3D structure during the localized arthritic stage. The reduction in bone marrow osteogenic potential in the advanced arthritic stage was due to the reduction in the number of total bone marrow cells, and differentiation of osteogenic cells was apparently unaffected. The reduction in bone formation may not be substantial in this arthritic model.

Citing Articles

Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis.

Ikic Matijasevic M, Flegar D, Kovacic N, Katavic V, Kelava T, Sucur A Clin Exp Immunol. 2016; 186(3):321-335.

PMID: 27612450 PMC: 5108074. DOI: 10.1111/cei.12862.


Reactivity of rat bone marrow-derived macrophages to neurotransmitter stimulation in the context of collagen II-induced arthritis.

Muschter D, Gottl C, Vogel M, Grifka J, Straub R, Grassel S Arthritis Res Ther. 2015; 17:169.

PMID: 26104678 PMC: 4496866. DOI: 10.1186/s13075-015-0684-4.


Quantifying not only bone loss, but also soft tissue swelling, in a murine inflammatory arthritis model using micro-computed tomography.

Perilli E, Cantley M, Marino V, Crotti T, Smith M, Haynes D Scand J Immunol. 2014; 81(2):142-50.

PMID: 25424522 PMC: 4329396. DOI: 10.1111/sji.12259.


Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201).

Dagley A, Ennis J, Turner J, Rood K, Van Wettere A, Gowen B Antiviral Res. 2014; 108:1-9.

PMID: 24833276 PMC: 4101997. DOI: 10.1016/j.antiviral.2014.05.004.


Induction of bone loss in DBA/1J mice immunized with citrullinated autologous mouse type II collagen in the absence of adjuvant.

Dusad A, Duryee M, Shaw A, Klassen L, Anderson D, Wang D Immunol Res. 2013; 58(1):51-60.

PMID: 24371010 DOI: 10.1007/s12026-013-8479-7.